ClinicalTrials.gg
Enrolling by invitationNCT05418894Updated Nov 12, 2026

Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing

An interventional study of Device: Directional Deep Brain Stimulation in Treatment Resistant Depression and Epilepsy, sponsored by Baylor College of Medicine. Enrolling by invitation at 1 site in United States. Open to participants aged 22 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Baylor College of Medicine · Not applicable, Interventional, and Basic science

How we know

Updated Nov 12, 2026Now Enrolling by invitationPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
22 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Planned enrollment
56th of 181
84 · median 38
Started
2022
with 12 others
No phase
72 of 205
21 open now
Primary completion
2031-03
later than 58 of 64 live
Registered
142nd of 205
by date

Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 56th largest by planned enrollment of the 181 interventional ones that give a count, is one of 13 that started in 2022, is one of 72 with no phase, reaches primary completion later than 58 of the 64 other live ones, and was the 142nd registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 22 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

The overall goal of this study is to map the spatiotemporal dynamics of social affective processing and to examine selective modulation of these dynamics in humans undergoing invasive intracranial monitoring for treatment-resistant epilepsy and depression. Pursuing this signal from a novel platform with invasive intracranial recording electrodes provides much-needed spatial and temporal resolution to characterize the neural dynamics of socio-affective processing. The investigators will leverage first-in-human intracranial neural recording opportunities created by a novel therapeutic platform termed "stereotactic electroencephalography-informed deep brain stimulation" (stereo-EEG-informed DBS), as well as the powerful platform of intracranial stereotactic recording and stimulation in patients undergoing epilepsy surgical evaluation at Baylor College of Medicine. The sEEG-informed DBS trial provides unique opportunities for intracranial recording of affect-relevant network regions in patients with treatment-resistant depression (TRD). Recordings in identical regions in epilepsy patients who themselves often demonstrate mild-moderate depressive symptoms will provide a wide dynamic range across the symptom spectrum. To provide critical data on the spatiotemporal dynamics of socio-affective processing the investigators will leverage these two human intracranial recording and stimulation cohorts to study the precise structural, functional, and causal properties of the affective salience network. Greater understanding of the social processing circuitry mediated by the affective salience network may be used to drive therapeutic innovation, pioneering a new paradigm that improves socio-emotional function across a wide variety of neuropsychiatric conditions. The results from this proposal have the potential to improve the lives of patients with dysfunction in social affective processing, with implications for a wide range of neuropsychiatric diseases.

03

Conditions studied

  • Treatment Resistant Depression
  • Epilepsy

Keywords

  • Deep Brain Stimulation
  • Neuromodulation
04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women (non-pregnant) between ages 22 and 70;
  2. diagnosis (assessed by Structured Clinical Interview for DSM-5 Axis I disorders SCID-5) of major depression disorder (MDD) as the primary diagnosis. A current major depressive episode (MDE), recurrent or single episode with first episode before age 60, secondary to nonpsychotic unipolar major depressive disorder;
  3. Chronic illness with current MDE ≥24 months duration and/or recurrent illness with at least a total of 2 lifetime episodes (including current episode >12 months);
  4. Treatment resistance (defined by criteria on the Antidepressant Treatment History Form ATHF): Failure (i.e. persistence of the major depressive episode) to respond to a minimum of four adequate depression treatments from at least two different treatment categories (e.g. SSRIs, SNRIs, TCAs, other antidepressants, lithium-addition, irreversible MAOIs, antidepressant augmentation with an atypical antipsychotic medication);
  5. Previous trial of Electroconvulsive Therapy (ECT) (lifetime): either did not respond, , poorly tolerated or refused. If refused, will discuss reasons and ensure subject understands relative risks of ECT versus DBS. We will try to enrich sample with patients who had previously shown response to ECT (or another intervention) that was partial or un-sustained;
  6. Symptom severity for Screening: Hamilton Depression Rating Scale-17 item (HDRS17)

    ≥20;

  7. The HDRS17 must remain greater than or equal to 20 on two separate assessments (at initial screening and 1 week before surgery), over a 1-month period;
  8. Symptom severity for Outcome: Montgomery Asberg Rating Scale (MADRS) ≥27 to be met at assessment one-week pre-op;
  9. Lifetime exposure to minimal 6 weeks of psychotherapy without sustained response;
  10. Must have a brain MRI within 3 months of enrollment that is "normal", according to the radiology report, or does not reveal any findings that in the opinion of the Investigator preclude participation in the study;
  11. Stable antidepressant medication regimen for the month preceding surgery;
  12. Modified (MMSE) score ≥ 24;
  13. Normal thyroid stimulating hormone (TSH) level within 12 months of study entry;
  14. The patient does not have any medical or physical conditions which, in the opinion of the Investigator, make it unlikely the patient will be able to participate for the duration of the study;
  15. Able and willing to give and agree to attend regular clinic visits for at least 12 months following surgery;
  16. Must have a treating psychiatrist, a family member, significant other/living partner, a caregiver, or a person known by the subject present at the Screening visit for the discussion about the study before co-signing the informed consent form;
  17. Willingness to sign Treatment Contract;
  18. Agrees to be followed at regular intervals by a licensed psychiatrist and to provide written permission allowing any and all forms of communication between the research team and the subject's healthcare providers, for the entirety of the study;
  19. Both male and female patients who undergo placement of intracranial electrodes for clinical characterization of epilepsy.

Exclusion criteria

Exclusion Criteria:

  1. Axis I Disorders: any lifetime history of psychotic disorder (e.g., schizophrenia, schizoaffective disorder);
  2. Bipolar disorder with rapid cycling and history of manic episode requiring hospitalization within the past 5 years;
  3. Cluster A or B personality disorder;
  4. Alcohol or substance use disorder within 6 months, excluding nicotine;
  5. Urine drug test positive for illicit drugs;
  6. Any evidence or indication of suicidal intent, suicidal attempt, or suicidal behavior, including but not limited to the C-SSRS score, within the past one year;
  7. Neurological/Medical condition that makes the patient, in the opinion of the surgeon, a poor surgical candidate (e.g., progressive neurodegenerative disorder, significant cardiopulmonary disorder, need for chronic anticoagulation);
  8. Any history of seizure disorder, hemorrhagic stroke, or has high risk of seizure (history of congenital brain malformation, history of brain injury, neuro-developmental disorder, currently taking medication that is known to lower seizure threshold, or other factors that predispose seizures);
  9. Any medical to surgery such as infection;
  10. Coagulopathy: Bleeding propensity and/or one of the following: > 1.5; prolonged activated partial thromboplastin time (aPTT) ≥ 45 sec; count \< 100×103/uL;
  11. A blood pressure of ≥ 180/110 mmHg at a single visit and evidence of cardiovascular disease (CVD);
  12. Participation in another drug, device, or biological trial within 90 days;
  13. Current implanted stimulation devices including cardiac pacemakers, defibrillators, and neurostimulators including spinal cord stimulators and deep brain stimulators;
  14. Pregnant or has plans to become pregnant in the next 24 months;
  15. Anticipated need for MRI;
  16. Need for Diathermy;
  17. Chronic use of anticoagulant or anti-platelet agents that cannot be safely stopped for a sufficient duration (minimum 2.5 weeks) in the peri-operative period.
  18. Any Psychiatric/Neurological/Medical condition that makes the subject, in the opinion of the Investigator, a poor candidate.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • No intervention
    EMU

    Patient's behavioral and neural activity via computer tasks and questionnaires are monitored in the Epilepsy Monitoring Unit

  • Experimental
    TRD

    Device: Device: Directional Deep Brain Stimulation

Interventions

  • DeviceDevice: Directional Deep Brain Stimulation

    Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation

06

What researchers measure

Primary outcomes

  1. Number of streamlines connecting between intracranial stimulation volume and recording volumes.

    To characterize structural connectivity using diffusion-weighted neuroimaging, we will calculate the outcome measures of the number of streamlines connecting target points.

    Time frame: up to 8 weeks

  2. Evoked potentials arising from stimulation.

    To characterize short latency mono- or oligo-synaptic connections of the stimulation volumes to sEEG recording positions using the single pulse-evoked potentials (PEP) technique, the outcome measure will be the number of evoked potentials arising from applied stimulation.

    Time frame: up to 8 weeks

Secondary outcomes

  1. Spectral band power during mood-relevant cognitive task.

    We will characterize the electrophysiological function of the affective salience network via the outcome measure of local field potential recordings in terms of power spectral density during mood-relevant cognitive function.

    Time frame: up to 12 weeks

  2. Spectral band power following applied stimulation.

    We will measure the outcome measure of local field potential power spectral density following the application of research stimulation.

    Time frame: up to 8 weeks

  3. Match score between spectral band power matrix of desired state and stimulation-evoked state.

    We will implement a process of template-matching to align stimulation-evoked neural activity patterns with "desirable" neural state signatures, including natural and induced positive mood states, using spatiotemporal correlation matrix decomposition and machine learning dimensionality reduction. The outcome measure will be the degree of correlational match between desired state and various evoked states following stimulation.

    Time frame: up to 12 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Mar 2031, 107 months after the start.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 107 months is above that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2027 → Mar 2031 and completion Mar 2027 → Mar 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2022
First posted
Jun 14, 2022
StartActual
Apr 1, 2022
Primary completionEst.
Mar 31, 2031was Mar 2027
CompletionEst.
Mar 31, 2031was Mar 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Nov 12, 2026
Primary completion
Mar 31, 2027→Mar 31, 2031
Nov 12, 2026
Study completion
Mar 31, 2027→Mar 31, 2031
Nov 12, 2026
Contact
No study contact listed any more: removed b•••@bcm.edu · •••5060
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Enrolling by invitation
    Primary completion Mar 31, 2027→Mar 31, 2031
    Study completion Mar 31, 2027→Mar 31, 2031
    Contact No study contact listed any more: removed b•••@bcm.edu · •••5060
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05418894
Responsible party
Kelly Bijanki (Assistant Professor, Baylor College of Medicine) — Principal investigator
First posted
Jun 14, 2022
Start date
Apr 1, 2022
Primary completion
Mar 31, 2031 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion